3. Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage. (Brevetto)

Type

• Brevetto (Classe)
• Prodotto della ricerca (Classe)
• Brevetto (Classe)

Label

• 3. Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage. (Brevetto) (literal)

Anno

• 2001-01-01T00:00:00+01:00 (literal)

Alternative label

• Carmeliet P., Collen D., De Falco S., Ruvo M. (2001)
  3. Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage.
  WO 01/85796 A2
  (literal)

Titolo

• 3. Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage. (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Carmeliet P., Collen D., De Falco S., Ruvo M. (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#altreInformazioni

• The invention relates to molecules which can inhibit the binding of PlGF to its receptor (VEGFR-1), such as monoclonal antibodies and tetrameric peptides. The invention further relates to the use of these molecules to treat latter pathological processes. (literal)

Numero brevetto

• WO 01/85796 A2 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#descrizioneSinteticaDelProdotto

• The present invention relates to the field of pathological angiogenesis and arteriogenesis. In particular the invention describes a stress-induced phenotype in a transgenic mouse (PlGF -/-) which does not produce Placental Growth Factor (PlGF) and which demonstrates an impaired vascular endothelial growth factor (VEGF)- dependent response. It is revealed that PlGF-deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis, and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (oedema formation) and inflammatory disorders. The invention thus relates to molecules which can inhibit the binding of PlGF to its receptor (VEGFR-1). (literal)

Anno di deposito

• 2001 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• Istituto di Genetica e Biofisica (literal)

Titolo

• 3. Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage. (literal)

Prodotto di

• Institute of genetics and biophysics \"Adriano Buzzati Traverso\" (IGB) (Istituto)

Insieme di parole chiave

• Parole chiave di "3. Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage." (Insieme di parole chiave)

Incoming links:

Prodotto

• Institute of genetics and biophysics \"Adriano Buzzati Traverso\" (IGB) (Istituto)

Insieme di parole chiave di

• Parole chiave di "3. Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage." (Insieme di parole chiave)